RxDoctor Payments DataLook up a doctor →

Robert Sasser, MD

Internal Medicine · Louisville, KYNPI 1891889929

Payments from drug & device makers

$61,707in general payments, 2019–2025

Across 769 payments — averaging $80.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$51K
  • AstraZeneca$2K
  • AbbVie$1K
  • Amgen$1K
  • Pfizer$1K
  • Novo Nordisk$946
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$50,84082%
  • Food & beverage$10,72117%
  • Education$1460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,707 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$133,600
Medicare patients
318
Services billed
1,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$150,450
OzempicSemaglutide89$127,259
XareltoRivaroxaban44$59,485
Nurtec OdtRimegepant Sulfate24$58,310
JanuviaSitagliptin Phosphate37$45,453
FarxigaDapagliflozin Propanediol36$43,647
LinzessLinaclotide40$36,345
VraylarCariprazine Hcl22$33,288
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$29,315
Repatha SureclickEvolocumab19$24,537
JardianceEmpagliflozin24$23,450
Janumet XrSitagliptin Phos/Metformin Hcl23$23,006
MyrbetriqMirabegron25$21,356
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$21,209
EntrestoSacubitril/Valsartan16$20,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$1,044$208,759179 claims
Novo NordiskOzempic$946$127,25989 claims
AbbVieLinzess, Vraylar, Synthroid$1,220$73,307112 claims
MerckJanuvia, Janumet Xr$148$68,45960 claims
Johnson & JohnsonXarelto$233$59,48544 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,555$56,86748 claims
Boehringer IngelheimJardiance, Tradjenta$449$39,85535 claims
GSKTrelegy Ellipta, Incruse Ellipta$341$33,73053 claims
Astellas Pharma US IncMyrbetriq$219$21,35625 claims
NovartisEntresto$527$20,96516 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$359$13,61224 claims
Lilly USA, LLCMounjaro$479$10,71712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →